ProCE Banner Activity


Mantle Cell Lymphoma: Novel Therapeutic Strategies Using the New Generation of BTK Inhibitors


Watch this on-demand webcast and download the corresponding slideset to gain expert insight on using the latest generation of BTK inhibitors to improve outcomes for patients with mantle cell lymphoma.

Physicians: maximum of 1.00 AMA PRA Category 1 CreditTM

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC : maximum of 1.00 Medical Knowledge MOC point(s)

Registered Nurses : 1.00 Nursing contact hour and 0.75 pharmacology credits

Released: October 04, 2023

Expiration: October 03, 2024



Julie M. Vose

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Brad Kahl

Brad Kahl, MD

Professor of Medicine
Washington University School of Medicine
Director Lymphoma Program
Siteman Cancer Center
St. Louis, Missouri 

Provided by

This activity is developed with our educational partner, Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Lilly and Merck Sharp & Dohme, LLC.



Merck Sharp & Dohme, LLC


Clinical Care Options, LLC

ProCE Banner

Target Audience

This educational program is intended for hematologists, medical oncologists, nurses, pharmacists, and other HCPs who treat patients with MCL.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Mantle cell lymphoma (MCL).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal first-line treatment for patients with MCL who are not candidates for aggressive therapy

  • Develop BTKi-based therapeutic strategies for patients with newly diagnosed MCL who are eligible for ASCT

  • Plan BTKi-based therapeutic strategies for patients with R/R MCL, taking into consideration guideline recommendations, new indications, and recent practice-changing clinical trial results

  • Manage treatment-related symptoms in patients with MCL receiving BTKi-based therapy to optimize adherence and clinical outcomes

  • Identify patients with MCL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKi and BTKi-based combinations


Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie.

Primary Author

Brad Kahl, MD

Professor of Medicine
Washington University School of Medicine
Director Lymphoma Program
Siteman Cancer Center
St. Louis, Missouri 

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Incyte, Janssen, Kite, Novartis, Seattle Genetics, TG Therapeutics.

All of the relevant financial relationships of individuals for this activity have been mitigated.

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Clinical Care Options, LLC, the educational partner, do not have any relevant financial relationships to disclose with ineligible companies.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 04, 2023, through October 03, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Logo, company nameDescription automatically generatedIn support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

A blue and white signDescription automatically generated with low confidence

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70 of higher is needed to obtain MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1 contact hour and 0.75 contact hours in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1 contact hour (0.1CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-105-H01-P
Type of Activity: Knowledge